Cannon C, Borgatti A, Henson M, Husbands B
Veterinary Clinical Sciences Department, University of Minnesota, St Paul, MN, 55108, USA.
J Small Anim Pract. 2015 Jul;56(7):425-9. doi: 10.1111/jsap.12354. Epub 2015 Apr 1.
To describe a chemotherapy protocol combining lomustine and doxorubicin in canine histiocytic sarcoma, including outcomes and toxicity.
Retrospective review of case records for dogs with histiocytic sarcoma treated with lomustine and doxorubicin (± cyclophosphamide) alternating every 2 weeks. Data collected included signalment, clinical signs, clinicopathological abnormalities, extent of disease, response, toxicity, time to tumour progression and survival time.
Of 17 dogs, 15 had disseminated or metastatic disease. The median number of chemotherapy cycles (one dose of each drug) received was three; most dogs discontinued therapy due to progressive disease. Dose reductions or delays occurred in 18% of cycles. The overall response rate was 58%, with a median time to tumour progression of 185 (range, 59 to 268) days for responders. The overall median survival time was 185 (18 to 402) days. No significant prognostic factors were identified.
The protocol appeared well-tolerated, had some efficacy against canine histiocytic sarcoma in the study population and could be considered as an alternative to single-agent protocols; prospective comparison may be warranted.
描述一种将洛莫司汀和阿霉素联合用于犬组织细胞肉瘤的化疗方案，包括疗效和毒性。
回顾性分析17只接受洛莫司汀和阿霉素（±环磷酰胺）每2周交替治疗的组织细胞肉瘤犬的病例记录。收集的数据包括特征、临床症状、临床病理异常、疾病范围、反应、毒性、肿瘤进展时间和生存时间。
17只犬中，15只患有播散性或转移性疾病。接受化疗周期（每种药物一剂）的中位数为3个；大多数犬因疾病进展而停止治疗。18%的周期出现剂量减少或延迟。总缓解率为58%，缓解者的肿瘤进展中位数时间为185（范围59至268）天。总中位生存时间为185（18至402）天。未发现显著的预后因素。
该方案耐受性良好，对研究人群中的犬组织细胞肉瘤有一定疗效，可作为单药方案的替代方案；可能需要进行前瞻性比较。
